News Story: Full Text
Sponsored By
Gleolan for brain tumors
Please Click On The Above Banner For More Details
Braintumor Website


AVANIR Subsidiary Xenerex Biosciences and Peregrine Pharmaceuticals Announce Research Collaboration for Solid Tumor Cancer Antibody Therapeutics (PR Newswire)...human monoclonal antibody therapies for the treatment of solid tumor cancers.......commercialization and licensing of unique technologies for the treatment of cancer, primarily based on its ``collateral targeting technologies``......., is currently being studied in the U.S. in a Phase II trial for brain cancer and five Phase I trials for colorectal, pancreatic, bilia...- Jun 12 7:02 AM ET

IF the story does not appear below, Click HERE to view the text of the story!
Note: The original website is displayed below - we have no control over it and are not responsible for the content of it, we just report it! IF you click on anything below, it will take you off of our website!
Original Source:

(Everything below this line is from!)

Click HERE to return to brain tumor news headlines

Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2020 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557